Could this pharma stock help you become an ISA millionaire?

Roland Head considers two potential ISA buys ahead of this year’s April deadline.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in long-term dividend growth stocks within an ISA can be a great way to build wealth. You don’t have to pay capital gains tax if you sell and you can also receive dividends free of income tax.

Today I’m looking at two potential dividend growth buys. Can either of these stocks help you retire rich?

A growth market

The ageing populations of most developed countries should be good news for ConvaTec Group (LSE: CTEC), which produces a range of disposable products needed by patients with chronic conditions such as incontinence and stomas.

The group’s focus is on products which require regular repeat purchases, and where demand is expected to grow. ConvaTec’s share price initially performed strongly after its flotation in 2016, but the stock fell sharply in October last year after it warned that sales would fall below expectations due to supply disruptions.

A buying opportunity?

This fall could be a buying opportunity. The group’s recent results showed a fairly stable performance in 2017. And although supply problems are expected to impact sales during the first half of the year, organic sales are still expected to rise by 2.5% to 3% in 2018.

Analysts expect adjusted earnings to rise by 12.5% to 18 cents per share in 2018, putting the stock on a forecast P/E of 15.3. The dividend is expected to climb 20% to 6.8 cents per share, giving a prospective yield of 2.5%.

ConvaTec’s net debt remains a little too high in my view, at $1.5bn or 3 times EBITDA. But cash generation is generally good, which should help with debt reduction. If you buy into this company’s structural growth story, the current share price could be a decent entry point.

Specialist services

Cambian Group (LSE: CMBN) provides a range of specialist services to support children with behavioural problems and learning difficulties. Its share price slipped 4% lower today after the group reported a pre-tax loss of £9m for 2017.

This loss was the result of £11.2m of exceptional costs incurred last year, as the company repositions itself to focus on higher severity services, which are presumably more profitable.  

Stripping out these one-off costs gives an adjusted pre-tax profit of £2.2m for 2017, compared to a loss of £0.4m for 2016. The group’s after-tax adjusted earnings rose by 50% to 3.6p last year.

Cash returns

Cambian sold its Adult Services division at the end of 2016. Much of the cash from this sale was used to repay debt. Most of the remaining cash has now been returned to shareholders, who received a special dividend of £50m (27.1p per share) in 2017. A further £15m (8.2p per share) was returned to shareholders in February.

I’m pleased that management is showing discipline and returning surplus cash to shareholders. However, it does leave me wondering whether the company’s expansion opportunities may be limited.

My view

Chief executive Saleem Asaria says that 2018 will be “a year of consolidation” that’s needed before the company can return to growth. City analysts expect the group’s adjusted earnings to rise by 80% to 6.3p per share this year, and are forecasting an ordinary dividend of 2.9p.

These figures put the stock on a forecast P/E of 32 with a prospective yield of 1.4%. Given the uncertainty over future growth, the stock looks too expensive to me. I’d like to know more before considering an investment.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

What on earth’s going to happen to the BP share price in 2026?

Harvey Jones looks at how the BP share price is shaping up for the year ahead, and finds investors have…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Have a £20,000 lump sum? Here’s how to target a £8,667 yearly passive income

How to turn £20,000 into a £8,667 passive income? Our Foolish author explains one counterintuitive strategy to build such an…

Read more »

British coins and bank notes scattered on a surface
Dividend Shares

2 dividend stocks that yield double the current UK interest rate

Following the latest UK interest rate cut, Jon Smith points out a couple of options that offer generous income relative…

Read more »

Investing Articles

A 9% yield and now this! Check out the stunning Taylor Wimpey share price forecast for 2026

Harvey Jones has kept the faith in Taylor Wimpey shares despite a difficult run, bolstered by their incredible yield. Next…

Read more »

Investing Articles

How much do you need in an ISA to aim for a life-changing passive income of £30,000 a year?

Harvey Jones says ISA savers can transform their futures in 2026 by investing in FTSE 100 dividend stocks with huge…

Read more »

Investing Articles

My top 10 ISA and SIPP stocks in 2026

Find out why a FTSE 100 investment trust is now this writer's top holding across his Stocks and Shares ISA…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

£10,000 invested in Rolls-Royce shares 5 Christmases ago is now worth…

James Beard reflects on the post-pandemic Rolls-Royce share price rally and whether the group could become the UK’s most valuable…

Read more »

Investing Articles

Will Nvidia shares continue their epic run into 2026 and beyond?

Nvidia shares have an aura of invincibility as an AI boom continues to benefit the chipmaker. Can anything stop the…

Read more »